ZymoGenetics to Webcast Presentation at Morgan Stanley Global Healthcare Unplugged Conference

Business Wire, Sept 2, 2008

SEATTLE -- ZymoGenetics, Inc. (NASDAQ:ZGEN) announced today that Douglas E. Williams, Ph.D., President and Chief Scientific Officer, will provide an update on company activities at the Morgan Stanley Global Healthcare Unplugged Conference in New York on Tuesday, September 9, 2008 at 10:55 a.m. Eastern Daylight Time.

A live webcast of the presentation can be accessed by going to: www.zymogenetics.com. The webcast will be archived for 30 days.

About ZymoGenetics

ZymoGenetics discovers and develops novel protein therapeutics that are based on the Company's research and biological insights into key disease pathways. The Company developed and markets RECOTHROM([R]) Thrombin, topical (Recombinant), which is the first recombinant, plasma-free thrombin. Other product candidates span a wide array of clinical opportunities that include cancer, autoimmune and viral diseases. ZymoGenetics intends to commercialize product candidates through internal development, collaborations with partners, and out-licensing of patents from its extensive patent portfolio. For further information, visit www.zymogenetics.com.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the current intent and expectations of the management of ZymoGenetics. These statements are not guarantees of future actions and involve uncertainties that are difficult to predict. Except as required by law, ZymoGenetics undertakes no obligation to update any forward-looking or other statements in this press release, whether as a result of new information, future events or otherwise.